Review



atcc bone marrow derived mscs  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    ATCC atcc bone marrow derived mscs
    Atcc Bone Marrow Derived Mscs, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 794 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atcc+bone+marrow+derived+mscs/Bone+Marrow-Derived+Mesenchymal+Stem+Cells%3B+Normal%2C+Human/bio_rxiv__2025__05__28__656674-54-0-0
    Average 96 stars, based on 794 article reviews
    atcc bone marrow derived mscs - by Bioz Stars, 2026-10
    96/100 stars

    Images

    Related Articles

    other:

    Article Title: Let-7b-5p loaded Mesenchymal Stromal Cell Extracellular Vesicles reduce Pseudomonas - biofilm formation and inflammation in CF Bronchial Epithelial Cells
    Article Snippet: ATCC Bone Marrow-Derived MSCs were commercially sourced (Cat # PCS-500-012).



    Similar Products

    96
    ATCC atcc bone marrow derived mscs
    Atcc Bone Marrow Derived Mscs, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atcc+bone+marrow+derived+mscs/Bone+Marrow-Derived+Mesenchymal+Stem+Cells%3B+Normal%2C+Human/bio_rxiv__2025__05__28__656674-54-0-0
    Average 96 stars, based on 1 article reviews
    atcc bone marrow derived mscs - by Bioz Stars, 2026-10
    96/100 stars
      Buy from Supplier

    hffs  (ATCC)
    95
    ATCC hffs
    Hffs, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atcc+bone+marrow+derived+mscs/hTERT+BM-MSC%3B+hTERT+Immortalized%3B+Bone+Marrow+Derived+MSC%3B+Human/pm41580398-286-12-13
    Average 95 stars, based on 1 article reviews
    hffs - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    95
    ATCC human bone marrow mscs
    Human Bone Marrow Mscs, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atcc+bone+marrow+derived+mscs/Bone+Marrow-Derived+Mesenchymal+Stem+Cells%3B+Normal+Human/pmc12655624-3-42-47
    Average 95 stars, based on 1 article reviews
    human bone marrow mscs - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    95
    ATCC mitomycin c treated mefs
    Representative images of mESCs and EBs (A) mESCs maintained on mitomycin C-treated <t>MEFs</t> in ES-DMEM medium. The colonies exhibit compact and rounded morphology, indicative of pluripotency. Scale bar: 200 μm. (B) mESCs cultured on 0.1% gelatin-coated cell culture plate in ES-IMDM medium without MEFs. mESCs display slightly flattened colony morphology compared to feeder-containing culture condition. Scale bar: 200 μm. (C) EBs on 4 days of differentiation in serum differentiation medium. EBs show typical spherical morphology with defined borders. Scale bar: 200 μm.
    Mitomycin C Treated Mefs, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atcc+bone+marrow+derived+mscs/hTERT+BM-MSC%3B+hTERT+Immortalized%3B+Bone+Marrow+Derived+MSC%3B+Human/pmc12491523-287-16-20
    Average 95 stars, based on 1 article reviews
    mitomycin c treated mefs - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    99
    ATCC atcc basal msc media
    1Cxcl1 KO increases <t>MSC</t> osteoblast differentiation. A, Schematic showing generation of CRISPR/Cas9 <t>Cxcl1-KO</t> <t>MSCs.</t> RFP, red fluorescent protein. B, Cxcl1 measured via ELISA for Scr. Ctrl. and Cxcl1-KO MSCs; graph shows protein expression normalized to total protein. ANOVA statistical analysis was performed. C, Alizarin red staining of mineralization assay of Cxcl1-KO and Scr. Ctrl. MSCs ± osteogenic supplement; representative images of staining (top) and graph shows quantification of staining (bottom); ANOVA statistical analysis was performed. D, ALP activity of Cxcl1-KO sgRNA 2 and Scr. Ctrl. MSCs measured via conversion of pNPP substrate to colored p-Nitrophenol (pNP); ANOVA statistical analysis was performed of each condition at 40 minutes. E, qRT-PCR of Osx , Ocn , and Col1α1 osteoblast gene expression in Cxcl1-KO sgRNA 2 and Scr. Ctrl. MSCs ± OS; graphs represent relative fold change of gene expression normalized to r36B4. ANOVA statistical analysis was performed. F, qRT-PCR measurement of CXCL8 , RUNX2 , and OPN gene expression following siRNA targeting of CXLC8 or nontargeted Scr. Ctrl. siRNA in human MSCs and graphs represent relative fold change of gene expression normalized to r18S . ANOVA statistical analysis was performed. Osteo Supp, osteogenic supplement. ( A, Created with BioRender.com .)
    Atcc Basal Msc Media, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atcc+bone+marrow+derived+mscs/Mesenchymal+Stem+Cell+Basal+Medium+for+Adipose%2C+Umbilical+and+Bone+Marrow-derived+MSCs/pmc12319404-65-7-11
    Average 99 stars, based on 1 article reviews
    atcc basal msc media - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    94
    ATCC mesenchymal stem cell growth kit
    1Cxcl1 KO increases <t>MSC</t> osteoblast differentiation. A, Schematic showing generation of CRISPR/Cas9 <t>Cxcl1-KO</t> <t>MSCs.</t> RFP, red fluorescent protein. B, Cxcl1 measured via ELISA for Scr. Ctrl. and Cxcl1-KO MSCs; graph shows protein expression normalized to total protein. ANOVA statistical analysis was performed. C, Alizarin red staining of mineralization assay of Cxcl1-KO and Scr. Ctrl. MSCs ± osteogenic supplement; representative images of staining (top) and graph shows quantification of staining (bottom); ANOVA statistical analysis was performed. D, ALP activity of Cxcl1-KO sgRNA 2 and Scr. Ctrl. MSCs measured via conversion of pNPP substrate to colored p-Nitrophenol (pNP); ANOVA statistical analysis was performed of each condition at 40 minutes. E, qRT-PCR of Osx , Ocn , and Col1α1 osteoblast gene expression in Cxcl1-KO sgRNA 2 and Scr. Ctrl. MSCs ± OS; graphs represent relative fold change of gene expression normalized to r36B4. ANOVA statistical analysis was performed. F, qRT-PCR measurement of CXCL8 , RUNX2 , and OPN gene expression following siRNA targeting of CXLC8 or nontargeted Scr. Ctrl. siRNA in human MSCs and graphs represent relative fold change of gene expression normalized to r18S . ANOVA statistical analysis was performed. Osteo Supp, osteogenic supplement. ( A, Created with BioRender.com .)
    Mesenchymal Stem Cell Growth Kit, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atcc+bone+marrow+derived+mscs/Mesenchymal+Stem+Cell+Growth+Kit+for+Bone+Marrow-derived+MSCs/pm40659755-338-7-22
    Average 94 stars, based on 1 article reviews
    mesenchymal stem cell growth kit - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    95
    ATCC cf1 murine embryonic fibroblasts
    1Cxcl1 KO increases <t>MSC</t> osteoblast differentiation. A, Schematic showing generation of CRISPR/Cas9 <t>Cxcl1-KO</t> <t>MSCs.</t> RFP, red fluorescent protein. B, Cxcl1 measured via ELISA for Scr. Ctrl. and Cxcl1-KO MSCs; graph shows protein expression normalized to total protein. ANOVA statistical analysis was performed. C, Alizarin red staining of mineralization assay of Cxcl1-KO and Scr. Ctrl. MSCs ± osteogenic supplement; representative images of staining (top) and graph shows quantification of staining (bottom); ANOVA statistical analysis was performed. D, ALP activity of Cxcl1-KO sgRNA 2 and Scr. Ctrl. MSCs measured via conversion of pNPP substrate to colored p-Nitrophenol (pNP); ANOVA statistical analysis was performed of each condition at 40 minutes. E, qRT-PCR of Osx , Ocn , and Col1α1 osteoblast gene expression in Cxcl1-KO sgRNA 2 and Scr. Ctrl. MSCs ± OS; graphs represent relative fold change of gene expression normalized to r36B4. ANOVA statistical analysis was performed. F, qRT-PCR measurement of CXCL8 , RUNX2 , and OPN gene expression following siRNA targeting of CXLC8 or nontargeted Scr. Ctrl. siRNA in human MSCs and graphs represent relative fold change of gene expression normalized to r18S . ANOVA statistical analysis was performed. Osteo Supp, osteogenic supplement. ( A, Created with BioRender.com .)
    Cf1 Murine Embryonic Fibroblasts, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atcc+bone+marrow+derived+mscs/hTERT+BM-MSC%3B+hTERT+Immortalized%3B+Bone+Marrow+Derived+MSC%3B+Human/bio_rxiv__2025__06__13__659535-342-24-28
    Average 95 stars, based on 1 article reviews
    cf1 murine embryonic fibroblasts - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    99
    ATCC ccl 2 bone marrow derived mscs atcc
    1Cxcl1 KO increases <t>MSC</t> osteoblast differentiation. A, Schematic showing generation of CRISPR/Cas9 <t>Cxcl1-KO</t> <t>MSCs.</t> RFP, red fluorescent protein. B, Cxcl1 measured via ELISA for Scr. Ctrl. and Cxcl1-KO MSCs; graph shows protein expression normalized to total protein. ANOVA statistical analysis was performed. C, Alizarin red staining of mineralization assay of Cxcl1-KO and Scr. Ctrl. MSCs ± osteogenic supplement; representative images of staining (top) and graph shows quantification of staining (bottom); ANOVA statistical analysis was performed. D, ALP activity of Cxcl1-KO sgRNA 2 and Scr. Ctrl. MSCs measured via conversion of pNPP substrate to colored p-Nitrophenol (pNP); ANOVA statistical analysis was performed of each condition at 40 minutes. E, qRT-PCR of Osx , Ocn , and Col1α1 osteoblast gene expression in Cxcl1-KO sgRNA 2 and Scr. Ctrl. MSCs ± OS; graphs represent relative fold change of gene expression normalized to r36B4. ANOVA statistical analysis was performed. F, qRT-PCR measurement of CXCL8 , RUNX2 , and OPN gene expression following siRNA targeting of CXLC8 or nontargeted Scr. Ctrl. siRNA in human MSCs and graphs represent relative fold change of gene expression normalized to r18S . ANOVA statistical analysis was performed. Osteo Supp, osteogenic supplement. ( A, Created with BioRender.com .)
    Ccl 2 Bone Marrow Derived Mscs Atcc, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atcc+bone+marrow+derived+mscs/HeLa/pmc12146666__mmc4-173-9-13
    Average 99 stars, based on 1 article reviews
    ccl 2 bone marrow derived mscs atcc - by Bioz Stars, 2026-10
    99/100 stars
      Buy from Supplier

    95
    ATCC htert immortalized asc52telo
    1Cxcl1 KO increases <t>MSC</t> osteoblast differentiation. A, Schematic showing generation of CRISPR/Cas9 <t>Cxcl1-KO</t> <t>MSCs.</t> RFP, red fluorescent protein. B, Cxcl1 measured via ELISA for Scr. Ctrl. and Cxcl1-KO MSCs; graph shows protein expression normalized to total protein. ANOVA statistical analysis was performed. C, Alizarin red staining of mineralization assay of Cxcl1-KO and Scr. Ctrl. MSCs ± osteogenic supplement; representative images of staining (top) and graph shows quantification of staining (bottom); ANOVA statistical analysis was performed. D, ALP activity of Cxcl1-KO sgRNA 2 and Scr. Ctrl. MSCs measured via conversion of pNPP substrate to colored p-Nitrophenol (pNP); ANOVA statistical analysis was performed of each condition at 40 minutes. E, qRT-PCR of Osx , Ocn , and Col1α1 osteoblast gene expression in Cxcl1-KO sgRNA 2 and Scr. Ctrl. MSCs ± OS; graphs represent relative fold change of gene expression normalized to r36B4. ANOVA statistical analysis was performed. F, qRT-PCR measurement of CXCL8 , RUNX2 , and OPN gene expression following siRNA targeting of CXLC8 or nontargeted Scr. Ctrl. siRNA in human MSCs and graphs represent relative fold change of gene expression normalized to r18S . ANOVA statistical analysis was performed. Osteo Supp, osteogenic supplement. ( A, Created with BioRender.com .)
    Htert Immortalized Asc52telo, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/atcc+bone+marrow+derived+mscs/hTERT+BM-MSC%3B+hTERT+Immortalized%3B+Bone+Marrow+Derived+MSC%3B+Human/bio_rxiv__2025__05__13__653705-97-15-17
    Average 95 stars, based on 1 article reviews
    htert immortalized asc52telo - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    Image Search Results


    Representative images of mESCs and EBs (A) mESCs maintained on mitomycin C-treated MEFs in ES-DMEM medium. The colonies exhibit compact and rounded morphology, indicative of pluripotency. Scale bar: 200 μm. (B) mESCs cultured on 0.1% gelatin-coated cell culture plate in ES-IMDM medium without MEFs. mESCs display slightly flattened colony morphology compared to feeder-containing culture condition. Scale bar: 200 μm. (C) EBs on 4 days of differentiation in serum differentiation medium. EBs show typical spherical morphology with defined borders. Scale bar: 200 μm.

    Journal: STAR Protocols

    Article Title: Protocol for chromatin immunoprecipitation and hematovascular function assays with differentiated mouse embryonic stem cells

    doi: 10.1016/j.xpro.2025.104083

    Figure Lengend Snippet: Representative images of mESCs and EBs (A) mESCs maintained on mitomycin C-treated MEFs in ES-DMEM medium. The colonies exhibit compact and rounded morphology, indicative of pluripotency. Scale bar: 200 μm. (B) mESCs cultured on 0.1% gelatin-coated cell culture plate in ES-IMDM medium without MEFs. mESCs display slightly flattened colony morphology compared to feeder-containing culture condition. Scale bar: 200 μm. (C) EBs on 4 days of differentiation in serum differentiation medium. EBs show typical spherical morphology with defined borders. Scale bar: 200 μm.

    Article Snippet: Alternatives: For MEFs, alternatives to EmbryoMax Primary MEFs (Passage 3) include commercially available gamma irradiated or mitomycin C-treated MEFs from ATCC (SCRC-1040), GlobalStem/Thermo Fisher (GSC-6001G), Applied StemCell (ASF-1101).

    Techniques: Cell Culture

    1Cxcl1 KO increases MSC osteoblast differentiation. A, Schematic showing generation of CRISPR/Cas9 Cxcl1-KO MSCs. RFP, red fluorescent protein. B, Cxcl1 measured via ELISA for Scr. Ctrl. and Cxcl1-KO MSCs; graph shows protein expression normalized to total protein. ANOVA statistical analysis was performed. C, Alizarin red staining of mineralization assay of Cxcl1-KO and Scr. Ctrl. MSCs ± osteogenic supplement; representative images of staining (top) and graph shows quantification of staining (bottom); ANOVA statistical analysis was performed. D, ALP activity of Cxcl1-KO sgRNA 2 and Scr. Ctrl. MSCs measured via conversion of pNPP substrate to colored p-Nitrophenol (pNP); ANOVA statistical analysis was performed of each condition at 40 minutes. E, qRT-PCR of Osx , Ocn , and Col1α1 osteoblast gene expression in Cxcl1-KO sgRNA 2 and Scr. Ctrl. MSCs ± OS; graphs represent relative fold change of gene expression normalized to r36B4. ANOVA statistical analysis was performed. F, qRT-PCR measurement of CXCL8 , RUNX2 , and OPN gene expression following siRNA targeting of CXLC8 or nontargeted Scr. Ctrl. siRNA in human MSCs and graphs represent relative fold change of gene expression normalized to r18S . ANOVA statistical analysis was performed. Osteo Supp, osteogenic supplement. ( A, Created with BioRender.com .)

    Journal: Molecular Cancer Research

    Article Title: Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer

    doi: 10.1158/1541-7786.MCR-24-0672

    Figure Lengend Snippet: 1Cxcl1 KO increases MSC osteoblast differentiation. A, Schematic showing generation of CRISPR/Cas9 Cxcl1-KO MSCs. RFP, red fluorescent protein. B, Cxcl1 measured via ELISA for Scr. Ctrl. and Cxcl1-KO MSCs; graph shows protein expression normalized to total protein. ANOVA statistical analysis was performed. C, Alizarin red staining of mineralization assay of Cxcl1-KO and Scr. Ctrl. MSCs ± osteogenic supplement; representative images of staining (top) and graph shows quantification of staining (bottom); ANOVA statistical analysis was performed. D, ALP activity of Cxcl1-KO sgRNA 2 and Scr. Ctrl. MSCs measured via conversion of pNPP substrate to colored p-Nitrophenol (pNP); ANOVA statistical analysis was performed of each condition at 40 minutes. E, qRT-PCR of Osx , Ocn , and Col1α1 osteoblast gene expression in Cxcl1-KO sgRNA 2 and Scr. Ctrl. MSCs ± OS; graphs represent relative fold change of gene expression normalized to r36B4. ANOVA statistical analysis was performed. F, qRT-PCR measurement of CXCL8 , RUNX2 , and OPN gene expression following siRNA targeting of CXLC8 or nontargeted Scr. Ctrl. siRNA in human MSCs and graphs represent relative fold change of gene expression normalized to r18S . ANOVA statistical analysis was performed. Osteo Supp, osteogenic supplement. ( A, Created with BioRender.com .)

    Article Snippet: Human bone marrow–derived MSCs were cultured in ATCC Basal MSC media (ATCC, PCS-500-030).

    Techniques: CRISPR, Enzyme-linked Immunosorbent Assay, Expressing, Staining, Mineralization Assay, Activity Assay, Quantitative RT-PCR, Gene Expression

    2Cxcl1 KO affects CXCR1 expression and alters the MSC transcriptome. A, qRT-PCR of Cxcr1 in Scr. Ctrl. MSCs and Cxcl1-KO MSCs (sgRNA 2). Graph represents relative fold change of gene expression normalized to r36B4 . Two sample t test statistical analysis was performed. *, P < 0.05. B, Left, Cxcr1 gene expression in parental MSCs following siRNA targeting or nontargeted siRNA; graph represents relative fold change of gene expression normalized to r36B4 ; two sample t test statistical analysis was performed. Right, ALP activity of Cxcr1-KD and Scr. Ctrl. MSCs ± osteogenic supplement treatment measured via conversion of para-Nitrophenylphosphate to colored pNP. Two sample t test statistical analysis was performed at 120-minute time point. C, Gene ontology analysis of upregulated (left) and downregulated (right) pathways in Cxcl1-KO sgRNA 2 MSCs compared with Scr. Ctrl. MSCs. D, GSEA plots: regulation of Runx2 signaling and activity, collagen degradation, and sssembly of collagen fibrils and other multimeric structures; ( E ) qRT-PCR validation of Cxcl1-dependent changes to the MSC transcriptome Parm1 , Fibulin 1 , Periostin Postn , and Gas6 gene expression in Cxcl1-KO MSCs. ANOVA statistical analysis was performed.

    Journal: Molecular Cancer Research

    Article Title: Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer

    doi: 10.1158/1541-7786.MCR-24-0672

    Figure Lengend Snippet: 2Cxcl1 KO affects CXCR1 expression and alters the MSC transcriptome. A, qRT-PCR of Cxcr1 in Scr. Ctrl. MSCs and Cxcl1-KO MSCs (sgRNA 2). Graph represents relative fold change of gene expression normalized to r36B4 . Two sample t test statistical analysis was performed. *, P < 0.05. B, Left, Cxcr1 gene expression in parental MSCs following siRNA targeting or nontargeted siRNA; graph represents relative fold change of gene expression normalized to r36B4 ; two sample t test statistical analysis was performed. Right, ALP activity of Cxcr1-KD and Scr. Ctrl. MSCs ± osteogenic supplement treatment measured via conversion of para-Nitrophenylphosphate to colored pNP. Two sample t test statistical analysis was performed at 120-minute time point. C, Gene ontology analysis of upregulated (left) and downregulated (right) pathways in Cxcl1-KO sgRNA 2 MSCs compared with Scr. Ctrl. MSCs. D, GSEA plots: regulation of Runx2 signaling and activity, collagen degradation, and sssembly of collagen fibrils and other multimeric structures; ( E ) qRT-PCR validation of Cxcl1-dependent changes to the MSC transcriptome Parm1 , Fibulin 1 , Periostin Postn , and Gas6 gene expression in Cxcl1-KO MSCs. ANOVA statistical analysis was performed.

    Article Snippet: Human bone marrow–derived MSCs were cultured in ATCC Basal MSC media (ATCC, PCS-500-030).

    Techniques: Expressing, Quantitative RT-PCR, Gene Expression, Activity Assay, Biomarker Discovery

    3Cxcl1-KO MSCs suppress RM1 growth in vitro and in vivo . A, RM1-luciferase cell proliferation measured via luciferase expression (RLU, Relative Light Units) following overnight coculture with an equal number of Cxcl1-KO sgRNA 2 or Scr. Ctrl. MSCs; ANOVA statistical analysis was performed. B, RM1 proliferation in response to Cxcl1-KO sgRNA 2 or Scr. Ctrl. MSC CM; graph shows cell count using trypan blue exclusion assay; ANOVA statistical analysis was performed at day 3. C, SA-AXL3 cell proliferation in response to Cxcl1-KO sgRNA 2 or Scr. Ctrl. MSC CM; graph shows cell count using trypan blue exclusion assay; ANOVA statistical analysis was performed at day 3 and each condition was compared with each. ***, P < 0.001 and comparing Scr. Ctrl. CM with SA AXL cells in serum-free media unless noted. **, P < 0.01. PCa, prostate cancer. D, qRT-PCR gene expression of RM1 Cxcr1 and Cxcr2 ; graph represents relative fold change of gene expression normalized to Hprt and Scr. Ctrl. MSCs; ANOVA statistical analysis was performed. E, Bioluminescence imaging of RM1-luciferase growth in an intratibial tumor model in C57BL/6 male mice co-injected Cxcl1-KO sgRNA 2 or Scr. Ctrl. MSCs ( n = 15/group; left), graph represents quantitation of bioluminescence imaging (right); two sample t test statistical analysis was performed at days 9, 11, and 14. F, X-ray of tumor-bearing tibias. Left, representative images and right, quantification of osteolytic pit area normalized to total bone marrow cavity area. G, Trichrome stain of tumor-bearing tibia: left, representative images (scale bar 500 μm) and right, quantification of staining normalized to marrow cavity area (top right); two-sample t test statistical analysis was performed.

    Journal: Molecular Cancer Research

    Article Title: Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer

    doi: 10.1158/1541-7786.MCR-24-0672

    Figure Lengend Snippet: 3Cxcl1-KO MSCs suppress RM1 growth in vitro and in vivo . A, RM1-luciferase cell proliferation measured via luciferase expression (RLU, Relative Light Units) following overnight coculture with an equal number of Cxcl1-KO sgRNA 2 or Scr. Ctrl. MSCs; ANOVA statistical analysis was performed. B, RM1 proliferation in response to Cxcl1-KO sgRNA 2 or Scr. Ctrl. MSC CM; graph shows cell count using trypan blue exclusion assay; ANOVA statistical analysis was performed at day 3. C, SA-AXL3 cell proliferation in response to Cxcl1-KO sgRNA 2 or Scr. Ctrl. MSC CM; graph shows cell count using trypan blue exclusion assay; ANOVA statistical analysis was performed at day 3 and each condition was compared with each. ***, P < 0.001 and comparing Scr. Ctrl. CM with SA AXL cells in serum-free media unless noted. **, P < 0.01. PCa, prostate cancer. D, qRT-PCR gene expression of RM1 Cxcr1 and Cxcr2 ; graph represents relative fold change of gene expression normalized to Hprt and Scr. Ctrl. MSCs; ANOVA statistical analysis was performed. E, Bioluminescence imaging of RM1-luciferase growth in an intratibial tumor model in C57BL/6 male mice co-injected Cxcl1-KO sgRNA 2 or Scr. Ctrl. MSCs ( n = 15/group; left), graph represents quantitation of bioluminescence imaging (right); two sample t test statistical analysis was performed at days 9, 11, and 14. F, X-ray of tumor-bearing tibias. Left, representative images and right, quantification of osteolytic pit area normalized to total bone marrow cavity area. G, Trichrome stain of tumor-bearing tibia: left, representative images (scale bar 500 μm) and right, quantification of staining normalized to marrow cavity area (top right); two-sample t test statistical analysis was performed.

    Article Snippet: Human bone marrow–derived MSCs were cultured in ATCC Basal MSC media (ATCC, PCS-500-030).

    Techniques: In Vitro, In Vivo, Luciferase, Expressing, Cell Counting, Trypan Blue Exclusion Assay, Quantitative RT-PCR, Gene Expression, Imaging, Injection, Quantitation Assay, Staining

    4Cxcl1-KO MSCs suppress bone-metastatic prostate cancer growth and promote osteogenesis in vivo at 3:1 (PCa:MSCs) ratio. A, Bioluminescence imaging of RM1-luciferase growth in an intratibial tumor model in immunocompetent mice with 1 × 10 4 Cxcl1-KO sgRNA 2 or Scr. Ctrl. MSCs and 1 × 10 4 RM1 cells (left) or 5 × 10 3 MSCs and 1.5 × 10 4 RM1 cells (right). Tumor burden (top) and representative bioluminescence imaging of mice (bottom); two-sample t test statistical analyses were performed at day 5, 7, and 9. B, Trichrome staining of tumor-bearing tibia sections from 3:1 (PCa:MSCs) mice: left, representative image quantification of staining normalized to marrow cavity area (scale bar = 500 μm) and right, quantification of staining normalized to marrow cavity area; two-sample t test statistical analysis was performed. C, Fluorescent IHC of α-SMA in tumor-bearing tibia from both 1:1 and 3:1 (PCa:MSC) tumors [ n = 6 Scr. Ctrl (three each 10K/15K); n = 7 KO (three of 10K and four of 15K)]. Left, representative images from 3:1 ratio, with SMA-positive MSCs (gold) and nuclei stained with DAPI (blue; scale bar = 100 μm); right, graph shows quantitation of SMA pixel intensity; ANOVA statistical analysis was performed. PCa, prostate cancer.

    Journal: Molecular Cancer Research

    Article Title: Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer

    doi: 10.1158/1541-7786.MCR-24-0672

    Figure Lengend Snippet: 4Cxcl1-KO MSCs suppress bone-metastatic prostate cancer growth and promote osteogenesis in vivo at 3:1 (PCa:MSCs) ratio. A, Bioluminescence imaging of RM1-luciferase growth in an intratibial tumor model in immunocompetent mice with 1 × 10 4 Cxcl1-KO sgRNA 2 or Scr. Ctrl. MSCs and 1 × 10 4 RM1 cells (left) or 5 × 10 3 MSCs and 1.5 × 10 4 RM1 cells (right). Tumor burden (top) and representative bioluminescence imaging of mice (bottom); two-sample t test statistical analyses were performed at day 5, 7, and 9. B, Trichrome staining of tumor-bearing tibia sections from 3:1 (PCa:MSCs) mice: left, representative image quantification of staining normalized to marrow cavity area (scale bar = 500 μm) and right, quantification of staining normalized to marrow cavity area; two-sample t test statistical analysis was performed. C, Fluorescent IHC of α-SMA in tumor-bearing tibia from both 1:1 and 3:1 (PCa:MSC) tumors [ n = 6 Scr. Ctrl (three each 10K/15K); n = 7 KO (three of 10K and four of 15K)]. Left, representative images from 3:1 ratio, with SMA-positive MSCs (gold) and nuclei stained with DAPI (blue; scale bar = 100 μm); right, graph shows quantitation of SMA pixel intensity; ANOVA statistical analysis was performed. PCa, prostate cancer.

    Article Snippet: Human bone marrow–derived MSCs were cultured in ATCC Basal MSC media (ATCC, PCS-500-030).

    Techniques: In Vivo, Imaging, Luciferase, Staining, Quantitation Assay